BHC Stock Recent News

Private equity firms TPG and Blackstone are joining forces in a bid to acquire eye care company Bausch + Lomb BLCO, the Financial Times reported.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy™ full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform. “We're confident that U.S. surgeons will agree with what their Canadian.

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m.

Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1 LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today released Liver Health Trends Report in Action, the latest Liver Health Annual Trends Report dedicated to sparking actionable change to improve liver disease management and outcomes for patients. Healthcare provider (HCP) survey participants called for holistic, multi-disciplinary treatment approaches, consistent use of non-invasive screening tools (e.g.

Bausch Health NYSE: BHC stock has been on a wild ride recently, with a dramatic surge in value over the last month. The catalyst for this surge is a wave of rumors suggesting that Bausch + Lomb NYSE: BLCO, Bausch Health's spinoff eye care business, is considering a buyout.

BHC stock rises 14.7% in a week after a report surfaced that the company is in talks with Jefferies Financial Group to push out maturities on some of its debt.

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.

Bausch & Lomb stock surged on reports the American-Canadian eye health products firm is exploring a sale as it seeks to resolve issues related to its separation from its debt-laden parent company Bausch Health Cos Inc (NYSE:BHC).    According to a Financial Times report citing people familiar with the matter, Bausch & Lomb is working with Goldman Sachs to gauge interest from potential buyers.

Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported.